EAST WINDSOR, N.J. — Camber Pharmaceuticals announced that its parent company, Hetero, has entered into a partnership with the Gates Foundation to manufacture and supply a generic version of lenacapavir for HIV prevention. The collaboration aims to make the twice-yearly injectable pre-exposure prophylaxis (PrEP) treatment available at a dramatically reduced cost in low- and middle-income countries.
Through upfront funding and volume guarantees, the Gates Foundation and Hetero plan to produce generic lenacapavir for approximately $40 per patient per year, following a brief oral lead-in regimen. The agreement is designed to ensure sustainable, affordable access for national health systems as they expand HIV prevention programs.
“Hetero is pleased to partner with the Gates Foundation to create a pathway for the sustainable and affordable supply of lenacapavir,” said Dr. Vamsi Krishna, Managing Director of Hetero Group of Companies. “This collaboration reflects our commitment to ensuring access to innovative HIV medicines for patients in India and other low- and middle-income countries.”
For more than two decades, Hetero has been a global leader in antiretroviral (ARV) therapy, supplying about 40% of worldwide demand for HIV and AIDS medicines. Camber continues to support that mission in the United States by offering a growing portfolio of high-quality generic treatments for patients affected by HIV and AIDS.
